Fertility technology just minted a new unicorn. Glow, the AI-powered women’s health and fertility platform, has closed a $180 million funding round at a $1.2 billion valuation, according to Globes reporting. The raise vaults the company into a rarified tier at the intersection of reproductive health and artificial intelligence — a space that has quietly attracted enormous capital as both the clinical need and the technological capability converge.
The timing is no accident. AI is reshaping diagnostics and personalized medicine faster than most health systems can absorb, and fertility — long under-resourced, deeply personal, and notoriously expensive — has become a proving ground for what precision software can accomplish. For context on how AI is threading into enterprise health and productivity pipelines more broadly, Future Wire’s coverage of AI agent governance underscores just how rapidly autonomous systems are moving into consequential domains.
What $1.2 Billion Buys in Femtech
Glow’s platform combines cycle tracking, fertility prediction, and health data aggregation with machine learning models that refine recommendations based on individual user data over time. The company has built a substantial user base — millions of women rely on the app for everything from contraception planning to IVF cycle management. That scale of longitudinal health data is itself a competitive moat: the more data the models train on, the sharper the predictive accuracy becomes, creating a compounding advantage that is difficult for smaller rivals to replicate.
The $1.2 billion valuation represents a significant step up and signals that investors believe the addressable market — global fertility treatment spending runs into the tens of billions of dollars annually — justifies a premium. Fertility treatment remains one of the most financially and emotionally burdensome healthcare journeys a patient can undertake, and software that meaningfully improves outcomes or reduces the number of failed cycles commands real pricing power. Glow is positioned to sit at the center of that value chain, connecting patients, clinics, and insurers through a single data-rich platform.
Israeli Roots, Global Reach
The raise adds Glow to a growing list of Israeli-linked health and AI ventures drawing outsized global capital. The Israeli startup ecosystem has demonstrated a consistent ability to punch above its weight in deep-tech categories, and femtech is increasingly part of that story. The Israeli tech landscape has seen a surge of activity in 2026, with both acquisitions and late-stage raises accelerating as international investors look for differentiated AI bets outside the saturated U.S. market.
For Glow, the fresh capital is expected to fund expanded clinical partnerships, deeper integration with fertility clinic electronic health record systems, and continued model development. The company is also likely eyeing regulatory pathways in markets like the European Union, where digital health certification requirements are tightening but where reimbursement opportunities are correspondingly larger. Getting to unicorn status is one milestone. Building the infrastructure to operate at clinical scale across multiple regulatory jurisdictions is the harder, longer game — and it is precisely what this $180 million is meant to finance.
Fertility AI is no longer a niche curiosity. With Glow now valued at ten figures, it is a category that the broader health-tech industry will have to take seriously.
